留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

LINC00341通过MAPK通路抑制肺腺癌细胞增殖

马诗淇 丁毅 李敏 王梦慈 张思宇 冯树梅

马诗淇, 丁毅, 李敏, 王梦慈, 张思宇, 冯树梅. LINC00341通过MAPK通路抑制肺腺癌细胞增殖[J]. 昆明医科大学学报, 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403
引用本文: 马诗淇, 丁毅, 李敏, 王梦慈, 张思宇, 冯树梅. LINC00341通过MAPK通路抑制肺腺癌细胞增殖[J]. 昆明医科大学学报, 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403
Shiqi MA, Yi DING, Min LI, Mengci WANG, Siyu ZHANG, Shumei FENG. LINC00341 Inhibits the Proliferation of Lung Adenocarcinoma Cells Through the MAPK Pathway[J]. Journal of Kunming Medical University, 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403
Citation: Shiqi MA, Yi DING, Min LI, Mengci WANG, Siyu ZHANG, Shumei FENG. LINC00341 Inhibits the Proliferation of Lung Adenocarcinoma Cells Through the MAPK Pathway[J]. Journal of Kunming Medical University, 2023, 44(4): 1-8. doi: 10.12259/j.issn.2095-610X.S20230403

LINC00341通过MAPK通路抑制肺腺癌细胞增殖

doi: 10.12259/j.issn.2095-610X.S20230403
基金项目: 国家自然科学基金资助项目(81660324);新疆维吾尔自治区自然科学基金资助项目(2021D01C267)
详细信息
    作者简介:

    马诗淇(1998~),女,陕西渭南人,在读硕士研究生,主要从事肿瘤发病机制研究工作

    通讯作者:

    冯树梅, E-mail: 87391167@qq.com

  • 中图分类号: R734

LINC00341 Inhibits the Proliferation of Lung Adenocarcinoma Cells Through the MAPK Pathway

  • 摘要:   目的   探讨LINC00341对肺腺癌细胞增殖的影响及其潜在机制。   方法   在公共数据集SEO和TCGA中分析肺腺癌中LINC00341 mRNA的表达,ROC曲线分析其诊断价值,对RMA和OKAYAMA数据进行生存分析,并通过美国密歇根大学医院肺癌样本进行RNA-seq验证和ROC曲线分析;结合基因本体(gene otology,GO)分析LINC00341基因生物学功能;通过siRNA沉默LINC00341的表达,根据不同处理分为对照组(NT)和沉默组(siLINC00341),并验证细胞转染效率;采用WST-1和平板克隆实验检测细胞增殖能力;RNA亚细胞定位检测LINC00341定位,Western blotting检测其对MAPK信号通路相关蛋白表达水平的影响。   结果   LINC00341在肺腺癌组织中低表达(3个数据集P < 0.0001),ROC曲线分析表明其可作为肺腺癌的诊断标记物,同时低表达LINC00341与患者较好的预后相关( P = 0.004)。GO富集分析结果表明LINC00341主要与RNA聚合酶II启动子转录调控、蛋白质结合等有关。沉默LINC00341可以促进肺腺癌细胞的增殖(P < 0.05)和克隆形成( P < 0.05),且MAPK信号通路蛋白STAT3和ERK均被激活( P < 0.05),RNA定位显示LINC00341主要分布在细胞核。   结论   LINC00341可能在转录水平调控MAPK通路,进而抑制肺腺癌发展,并可作为肺腺癌重要的诊断和预后标志物。
  • 图  1  LINC00341 在肺腺癌细胞中的表达、ROC曲线以及生存分析

    A~C:UM,SEO和TCGA RNA测序数据集中,LUAD和正常肺组织样本中LINC00341表达水平散点图(3个数据集均P < 0.0001);D~F:LINC00341在UM,SEO和TCGA 3个数据集中AUC值的ROC曲线;G~H:Kaplan-Meier曲线对LINC00341的生存分析。P < 0.05。

    Figure  1.  Expression,ROC curve and survival of LINC00341 in lung adenocarcinoma cell

    图  2  LINC00341的GO富集分析

    A:靶基因生物学过程(BP)功能气泡图;B:靶基因分子功能(MF)功能气泡图。

    Figure  2.  GO enrichment analysis of LINC00341

    图  3  沉默LINC00341对PC-9细胞增殖能力的影响

    A:qRT-PCR检测转染效率;B:WST-1方法检测LINC00341沉默后细胞增殖能力;C~D:平板克隆实验检测LINC00341后细胞克隆形成能力。**P < 0.01,**** P < 0.0001。

    Figure  3.  Effect of silencing LINC00341 on proliferation ability of PC-9 cell

    图  4  沉默LINC00341对通路蛋白的影响以及LINC00341的亚细胞定位

    A:qRT-PCR显示LINC00341在肺腺癌细胞中的核和细胞质部分;B:Western blot检测LINC00341沉默后STAT3(信号传导及转录激酶蛋白),ERK1/2(细胞外调节蛋白激酶)和P38(丝裂原活化蛋白激酶)蛋白表达情况;C:各个目的蛋白相对表达水平。*P < 0.05,**P < 0.01,***P < 0.001。

    Figure  4.  Effect of silencing LINC00341 on proteins and subcellular localization of LINC00341

  • [1] Sung H,Ferlay J,Siegel R L,et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
    [2] Turner M C,Andersen Z J,Baccarelli A,et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations[J]. CA Cancer J Clin,2020, published online ahead of print.
    [3] Malhotra J,Malvezzi M,Negri E,et al. Risk factors for lung cancer worldwide[J]. Eur Respir J,2016,48(3):889-902.
    [4] Succony L,Rassl D M,Barker A P,et al. Adenocarcinoma spectrum lesions of the lung: Detection,pathology and treatment strategies[J]. Cancer Treat Rev,2021,99:102237. doi: 10.1016/j.ctrv.2021.102237
    [5] Guo C J,Ma X K,Xing Y H,et al. Distinct processing of lncRNAs contributes to non-conserved functions in stem cells[J]. Cell,2020,181(3):621-636.e622. doi: 10.1016/j.cell.2020.03.006
    [6] Qian X,Zhao J,Yeung P Y,et al. Revealing lncRNA structures and interactions by sequencing-based approaches[J]. Trends Biochem Sci,2019,44(1):33-52.
    [7] Nojima T,Proudfoot N J. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics[J]. Nat Rev Mol Cell Biol,2022,23(6):389-406. doi: 10.1038/s41580-021-00447-6
    [8] Slack F J,Chinnaiyan A M. The role of non-coding RNAs in oncology[J]. Cell,2019,179(5):1033-1055. doi: 10.1016/j.cell.2019.10.017
    [9] Wang H,Meng Q,Qian J,et al. Review: RNA-based diagnostic markers discovery and therapeutic targets development in cancer[J]. Pharmacol Ther,2022,234:108123. doi: 10.1016/j.pharmthera.2022.108123
    [10] Bhan A,Soleimani M,Mandal S S. Long noncoding RNA and cancer: A new paradigm[J]. Cancer Res,2017,77(15):3965-3981. doi: 10.1158/0008-5472.CAN-16-2634
    [11] Li S,Chen S,Wang B,et al. The long noncoding RNA LINC00341 suppresses colorectal carcinoma by preventing cell migration and apoptosis[J]. Cell Biochem Funct,2020,38(3):266-274. doi: 10.1002/cbf.3473
    [12] Yang Q,Li X,Zhou Y,et al. A LINC00341-mediated regulatory pathway supports chondrocyte survival and may prevent osteoarthritis progression[J]. J Cell Biochem,2019,120(6):10812-10820. doi: 10.1002/jcb.28372
    [13] Pan L,Tan Y,Wang B,et al. Caspase recruitment domain containing protein 9 suppresses non-small cell lung cancer proliferation and invasion via inhibiting MAPK/p38 pathway[J]. Cancer Res Treat,2020,52(3):867-885. doi: 10.4143/crt.2019.606
    [14] Zheng G,Shen Z,Chen H,et al. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway[J]. Biomed Pharmacother,2017,90:437-445. doi: 10.1016/j.biopha.2017.03.091
    [15] Okayama H,Kohno T,Ishii Y,et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas[J]. Cancer Res,2012,72(1):100-111. doi: 10.1158/0008-5472.CAN-11-1403
    [16] Irizarry R A,Hobbs B,Collin F,et al. Exploration,normalization,and summaries of high density oligonucleotide array probe level data[J]. Biostatistics,2003,4(2):249-264. doi: 10.1093/biostatistics/4.2.249
    [17] Seo J S,Ju Y S,Lee W C,et al. The transcriptional landscape and mutational profile of lung adenocarcinoma[J]. Genome Res,2012,22(11):2109-2119. doi: 10.1101/gr.145144.112
    [18] Cancer genome atlas research network. Comprehensive molecular profiling of lung adenocarcinoma [J]. Nature, 2014, 511(7511): 543-550.
    [19] Dhanasekaran S M,Balbin O A,Chen G,et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes[J]. Nat Commun,2014,5:5893. doi: 10.1038/ncomms6893
    [20] Liao Y,Wang J,Jaehnig E J,et al. WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs[J]. Nucleic Acids Res,2019,47(W1):W199-W205. doi: 10.1093/nar/gkz401
    [21] Yan H,Bu P. Non-coding RNA in cancer[J]. Essays Biochem,2021,65(4):625-639.
    [22] Zhang Y X,Yuan J,Gao Z M,et al. LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway[J]. Eur Rev Med Pharmacol Sci,2018,22(2):443-449.
    [23] Hua Q,Jin M,Mi B,et al. LINC01123,a c-Myc-activated long non-coding RNA,promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis[J]. J Hematol Oncol,2019,12(1):91. doi: 10.1186/s13045-019-0773-y
    [24] Del Real A,López-Delgado L,Sañudo C,et al. Long noncoding RNAs as bone marrow stem cell regulators in osteoporosis[J]. DNA Cell Biol,2020,39(9):1691-1699. doi: 10.1089/dna.2020.5672
    [25] Wang L,He Y,Liu W,et al. Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer[J]. Oncotarget,2016,7(10):11487-11499. doi: 10.18632/oncotarget.7203
    [26] Fang J Y,Richardson B C. The MAPK signalling pathways and colorectal cancer[J]. Lancet Oncol,2005,6(5):322-327. doi: 10.1016/S1470-2045(05)70168-6
    [27] Liu F,Yang X,Geng M,et al. Targeting ERK,an Achilles' Heel of the MAPK pathway,in cancer therapy[J]. Acta Pharm Sin B,2018,8(4):552-562. doi: 10.1016/j.apsb.2018.01.008
    [28] Ullah R,Yin Q,Snell A H,et al. RAF-MEK-ERK pathway in cancer evolution and treatment[J]. Semin Cancer Biol,2022,85:123-154.
    [29] Yang S H,Sharrocks A D,Whitmarsh A J. MAP kinase signalling cascades and transcriptional regulation[J]. Gene,2013,513(1):1-13. doi: 10.1016/j.gene.2012.10.033
    [30] Ye D,Li Y,Zhang H,et al. Silencing PRSS1 suppresses the growth and proliferation of gastric carcinoma cells via the ERK pathway[J]. Int J Biol Sci,2021,17(4):957-971. doi: 10.7150/ijbs.52591
    [31] Pranteda A,Piastra V,Stramucci L,et al. The p38 MAPK signaling activation in colorectal cancer upon therapeutic treatments[J]. Int J Mol Sci,2020,21(8):2773. doi: 10.3390/ijms21082773
    [32] Feng S,Zhang J,Su W,et al. Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer[J]. Sci Rep,2017,7(1):2982. doi: 10.1038/s41598-017-03043-x
    [33] Jiang Q G,Xiong C F,Lv Y X. Kin17 facilitates thyroid cancer cell proliferation,migration,and invasion by activating p38 MAPK signaling pathway[J]. Mol Cell Biochem,2021,476(2):727-739. doi: 10.1007/s11010-020-03939-9
  • [1] 杨晟强, 王平.  Hsp90抑制剂Ganetespib联合培美曲塞对肺腺癌细胞的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240705
    [2] 沈旺寻, 杨银煜, 李灿伟, 杨金荣, 伍思婧, 赵华君, 陀晓宇.  ROR1在不同组织学分级浸润性肺腺癌中的表达与临床意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240509
    [3] 杨红秀, 朱中山.  肺腺癌中HPRT1基因表达对患者总生存的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240803
    [4] 宋飞, 车佳音, 黄明, 徐丹, 李红阳, 李定坤, 向盈盈.  放射性125I粒子在肺腺癌EMT及临床治疗中的作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230101
    [5] 刘邦卿, 李剑锋, 刘晓辉, 张劲男, 梁金屏.  miR-196b靶向ERG促进肺腺癌的增殖和迁移, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231023
    [6] 赵华君, 潘国庆, 唐莹, 王智园, 赵晓玮, 陀晓宇.  ROR1在肺腺癌组织中的表达与气腔播散相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221128
    [7] 朱中山, 杨洲, 江承川, 李小兵, 任斗, 黄橙, 张维薇, 李湘军, 赵顺利.  肺腺癌患者PLA2G1B表达情况与预后的相关性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220912
    [8] 吴茂芳, 周永春, 蔡静静, 莫欣, 李瑛玮, 毛佳惠.  云南地区多结节肺腺癌EGFR突变及其临床意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220215
    [9] 王应霞, 何琴, 王国芳, 张旋.  非小细胞肺癌中microRNA-21和EGFR的表达及意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210818
    [10] 段宏民, 陈楠, 杨永燕, 李云霞, 冯金象, 李航, 黄秀文, 吕东津, 张明, 赵玉涛.  安罗替尼对肺腺癌细胞株A549放射敏感性的影响及机制, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210808
    [11] 马燕粉, 胡建, 张宁, 武倩, 王晓琴.  肺腺癌性与结核性胸腔积液患者凝血指标变化及异常模式, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211021
    [12] 马国玉, 熊庆, 蒋国庆, 杨家甜, 木云珍.  基于生物信息学方法识别肺腺癌预后相关基因, 昆明医科大学学报.
    [13] 吴琪燕, 边革元, 程绘珺, 李娇霞, 王书廷, 黄照略.  肺腺癌预后因素及血清肿瘤标记物的诊断效能, 昆明医科大学学报.
    [14] 朱中山, 严文辉, 李小兵, 杨洲, 白鹏.  200例肺腺癌脑转移患者驱动基因突变情况及预后关系, 昆明医科大学学报.
    [15] 隋念含.  甲基苯丙胺依赖大鼠纹状体RGS4和D2受体信号传导通路mRNA的表达, 昆明医科大学学报.
    [16] 王华.  吉非替尼治疗晚期肺腺癌临床观察, 昆明医科大学学报.
    [17] 肺腺癌A549细胞株GDNF、BDNF、NT3和NT4的表达, 昆明医科大学学报.
    [18] 肺腺癌A549细胞株细胞活力变化及GDNF表达, 昆明医科大学学报.
    [19] 宣威肺腺癌xwlc-05和肺腺癌A549细胞株体外培养细胞活力的比较研究, 昆明医科大学学报.
    [20] 肺腺癌A549细胞中Nestin的表达, 昆明医科大学学报.
  • 加载中
图(4)
计量
  • 文章访问数:  3277
  • HTML全文浏览量:  1937
  • PDF下载量:  21
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-12-23
  • 刊出日期:  2023-04-25

目录

    /

    返回文章
    返回